MedTrace Logo

Third Line Highly Active Antiretroviral Therapy (HAART) in HIV-infected Children

NCT01225406 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2020-07-17

No results posted yet for this study

Summary

This is an observational cohort study of virologic and immunologic outcome after at least 48 weeks of third line antiretroviral therapy. Upto 150 children at 8 Thai sites will be enrolled. Third line antiretroviral therapy in this study is defined as an antiretroviral (ARV) regimen in a patient who has failure or intolerance to first line NNRTI-based therapy and second line PI-based therapy. Such regimens may contain new drugs or drug classes such as darunavir, tipranavir, etravirine and raltegravir The knowledge gained from this study will help the Thai government in planning its strategy to provide third line ARV therapy to children within the national program.

Conditions

  • This Study is Designed to Collect Treatment Data of Thai Children on Third Line ARV Therapy

Interventions

DRUG

Tenofovir

Sponsors & Collaborators

  • Ministry of Education, Thailand

    collaborator OTHER

  • National Health Security Office, Thailand

    collaborator OTHER

  • The HIV Netherlands Australia Thailand Research Collaboration

    lead OTHER

Principal Investigators

  • Thanyawee Puthanakit, MD · Chulalongkorn University Bangkok

  • Kulkanya Chokephaibulkit, MD · Siriraj Hospital

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2013-08-31
Completion
2013-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01225406 on ClinicalTrials.gov